Please visit our MS learning channel on Youtube, which provides hundreds of topics from our education programs, that were video-recorded and archived here: www.youtube.com/msviewsandnews -- Be empowered with MS news by registering with us: www.register.msviewsandnews.org

joomla ecommerce template -- Scroll left side of this blog for needed resources. Also, use our 'search by topic' tool, to find specific information.

Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.

============================================================

Monday, October 20, 2014

Results from Two Phase III Studies (7mg and 14mg dosages) Added to U.S. Label of Genzyme’s Aubagio

Once-daily Aubagio is the only oral treatment to significantly slow progression of disability in two Phase III studies of patients with relapsing multiple sclerosis (TEMSO and TOWER), and to have positive data on early MS (TOPIC) in its label
Monday, October 20, 2014 10:35 am EDT

Dateline:

CAMBRIDGE, Mass.

"These data, along with its consistent safety and tolerability profile, make Aubagio an important treatment option for patients with relapsing MS."

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genzyme, a Sanofi company, announced today that the Food and Drug Administration (FDA) has approved the inclusion of efficacy and safety data from the TOWER and TOPIC studies of once-daily, oral Aubagio® (teriflunomide) in the product’s U.S. label.
In the TOWER study, patients with relapsing MS receiving Aubagio 14 mg had a statistically significant reduction in annualized relapse rate and relative risk of sustained disability progression compared to placebo. In addition, a significant reduction in annualized relapse rate was observed in patients treated with Aubagio 7 mg compared to placebo.
The TOPIC study was designed to assess whether initiation of Aubagio in patients who experienced their first neurological symptoms suggestive of MS could prevent or delay a second clinical attack (i.e., relapse). In this study, the proportion of patients free of relapse was statistically significantly greater for Aubagio 14 mg and 7 mg, compared to placebo. Results of the TOPIC study were published inThe Lancet Neurology in September 2014.
Aubagio is the only oral multiple sclerosis treatment that has demonstrated a positive effect on disability progression in two Phase III clinical studies and is the only oral therapy with supporting published efficacy data on the treatment of patients who have experienced a first clinical attack,” said Dr. Aaron E. Miller, Medical Director, The Corinne Goldsmith Dickinson Center for Multiple Sclerosis, The Mount Sinai Hospital. “These data, along with its consistent safety and tolerability profile, make Aubagio an important treatment option for patients with relapsing MS.”
Aubagio was approved by the FDA in September 2012 based on data from the Phase III TEMSO study, in which patients with relapsing MS who received Aubagio 14 mg had a statistically significant reduction in annualized relapse rate and relative risk of sustained disability progression compared to placebo. Patients who received Aubagio 7 mg had a statistically significant reduction in annualized relapse rate compared to placebo.
The update to the U.S. label reflects the breadth of data reinforcing the consistent efficacy of Aubagio,” said Genzyme President and CEO, David Meeker, M.D. “Aubagio is establishing itself within the MS treatment paradigm due to its efficacy, as well as its safety and tolerability as demonstrated during its two years on the market.
Pooled safety analyses from more than 2,000 patients who received Aubagio in all three Phase III studies were added to the label. In the MS clinical studies with Aubagio, the incidence of serious adverse events were similar among Aubagio and placebo-treated patients. Serious events may include decreased white blood cell count, peripheral neuropathy, skin reactions and increased blood pressure. The most common adverse events associated with Aubagio in MS patients included headache, diarrhea, nausea, alopecia and increase in ALT.
About Aubagio® (teriflunomide)
Aubagio is approved in more than 50 countries around the world, including the United States, European Union, Australia, Argentina, Brazil, Canada, Chile, Columbia, Dominican Republic, Guatemala, Honduras, Mexico, New Zealand, Panama, Peru, Russia, South Korea, Switzerland, Turkey and Ukraine, with additional marketing applications under review by regulatory authorities globally. Between clinical trials and commercial use, approximately 30,000 patients have been treated with Aubagio.
Aubagio is an immunomodulator with anti-inflammatory properties. Although the exact mechanism of action for Aubagio is not fully understood, it may involve a reduction in the number of activated lymphocytes in the central nervous system (CNS). Aubagio is supported by one of the largest clinical programs of any MS therapy, with more than 5,000 trial participants in 36 countries.
U.S. Indication and Usage
Aubagio (teriflunomide) is a once-daily, oral therapy indicated for the treatment of adult patients with relapsing forms of multiple sclerosis. The recommended dose of Aubagio is 7 mg or 14 mg orally once-daily.
Important Safety Information About Aubagio
Continue reading



~~~~~~~~~~~~~~~~~~~~
 Keep CURRENT and up to date,
with MS Views and News 
OPT-IN here
.

WATCH OUR Multiple Sclerosis recorded
 EDUCATIONAL VIDEOS by Topic: 

.


1 comment:

Anonymous said...

WOW just what I was searching for. Came here by searching
for repair manuals